Upharmacia March 2017
PHARMA MARKET NEWS
Roche Won Lawsuit
Against the
MOH
In on Mar 1, the Kyiv Economic Court satisfied the suit of F. Hoffmann- LA Roche AG on termination of the violation of patent ownership rights. The suit was against Hetero Labs Limited company regarding illegal registration by the MOH of the drugs containing capecitabine. In 2015, the MOH registered two drugs CAPECITABINE( Hetero Labs Limited, India), ignoring the patent for the substance granted to Roche in 2001. After conducting legal expertise in the field of intellectual property, the Court decided to satisfy the claim of Roche and to cancel the registration of the drugs. Capecitabine is used for the treatment of different types of cancer. It is released by Roche under the brand name XELODA ®.
Arterium Launched Antibacterial Uroseptic
Arterium Corporation expanded its portfolio with antibacterial uroseptic Urofoscin( fosfomycin). The drug is used for the treatment of acute bacterial infections of the urinary tract, in particular – acute cystitis. One sachet of Urofoscin is effective for the treatment of acute phase of cystitis. The drug is produced at the facilities of Kievmedpreparat.
Arterium Corporation was the second company on the Ukrainian pharmaceutical market by retail sales in 2016. Antiinfectives for systemic use provide about 25 % of the total income to the company.
Antimonopoly Committee Analyzed Pharma Market
On 14 Mar, the Antimonopoly Committee of Ukraine( ACU) presented its Report for 2016. The special chapter of the Report was dedicated to the pharmaceutical market of Ukraine.
The Committee defined the following issues with the functioning of the pharmaceutical market:
• The lack of the common approach to regulation of the markets;
• The lack of harmonized and interconnected regulatory acts;
• The inconsistency of regulatory acts of the MOH;
• A lot of remarks regarding the initial stage of implementation of certain programs on reimbursement and reference pricing of medicines;
• Insufficient development of health insurance, etc. Moreover, according to the ACU, the existing system allows all members of drug promotion chain to shift all financial risks to the customer. Thus, the Committee stated that self-regulation of the pharmaceutical market of Ukraine is inefficient.
The ACU also presented its propositions to solve the issues of the market:
• Introduction of reference pricing in regard to the most essential medicines to increase their affordability and launch a gradual movement towards reference pricing on all drugs;
• Introduction of provisions on electronic registries of patients for the types of diseases treated for the state( local) budget;
• Gradual movement from the current system of state price regulation( through setting mark-ups) to the introduction of reimbursement system;
• Change of the model of healthcare provision through the introduction of compulsory social medical insurance;
• Introduction of the term“ medical service” in the legislation;
• Establishing transparent relations in the sphere of promotion and marketing of medicines with consideration of the European experience;
• Amendments to the License
6 www. upharma-c. com